ClinicalTrials.gg
Not yet recruitingNCT07105267FELICITAUpdated Aug 5, 2025

Open Label Phase IIa Trial Evaluating the Effect and Safety of Transplantation of Fecal Microbiota in Children With Autism Spectrum Disorders and Gastrointestinal Symptoms

A Phase 2 interventional study of FMT Protocol in Autism Spectrum Disorder and Fecal Microbiota Transplantation (FMT), sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 36 Months to 72 Months. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
36 Months to 72 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris — 10 open to participants now, 11 under way, none of them phase 3. Autism Spectrum Disorder · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
13th of 13
5 · median 27
Started
2025
with 1 other
Phase 2
3 of 17
2 open now
Primary completion
2027-04
later than 3 of 10 live
Registered
13th of 17
by date

Among the 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 2, reaches primary completion later than 3 of the 10 other live ones, and was the 13th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

10 of the 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 36 Months to 72 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Autism Spectrum Disorder by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Autism Spectrum Disorders (ASD), affect approximately 1% of the general population and are characterized by impairments in social communication associated with repetitive/stereotyped behaviors. Approximately one-third of these patients display gastrointestinal (GI) symptoms, and a growing number of studies suggest abnormalities of gut microbiota in ASD. Gut microbiota and the brain interact through complex pathways. Preliminary evidence in adults with ASD suggests that modulation of the gut microbiota by probiotics and/or prebiotics and more recently by fecal microbiota transplantation could improve GI symptoms but also socio-communication deficit, with persistent improvement at year 2.

Read the detailed description
  1. Screening :

    Screening will be done in ASD units of child psychiatry departments of Robert Debré

  2. Information of patients and their families Information will be delivered in the child psychiatry department of Robert Debré hospital.
  3. Inclusion Consent will be collected in CIC of Robert Debré hospital during the initial visit by child psychiatrist 7 to 15 days after information from the patient's family.
  4. Patient follow-up during trial Initial visit: for parents and patient information. Further visits (W4, W18, W24, M12): treatment administrations will be done at the CIC. Subjects will be evaluated on efficacy and safety and acceptability. Stool, urine and blood samples will be collected.

    Phone visits (W11 and M9): Safety and the Acceptability questionnaire (parents) will be evaluated.

  5. Products: donor and transplant preparation
  6. Same administration schedule in FMT

    • D1 to D4: Vancomycin (10mg/kg, 4 times a day). 1st dose in the CIC, the 3 others at home
    • D4: Picoprep® treatment at home
    • D5: First FMT using rectal enema (100ml = 25g of stool from donor) using Foley probe (rectal administration) in CIC
    • D12: Second FMT using rectal enema (100ml = 25g of stool from donor) using Foley probe (rectal administration) in CIC
    • D19: Third FMT using rectal enema (100ml = 25g of stool from donor) using Foley probe (rectal administration) in CIC
03

Conditions studied

  • Autism Spectrum Disorder
  • Fecal Microbiota Transplantation (FMT)

Keywords

  • Austim Spectrum Disorder
  • FMT
  • gastrointestinal symptom,
04

Who can participate

Ages eligible
36 Months to 72 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASD diagnosis based on criteria
  • Gastrointestinal symptoms: at least a score of 5 on 1 of the 5 GSRS domains (diarrhea, abdominal pain, constipation, indigestion, reflux) for over a period of 1 year or more
  • Age between 36 and 72 months
  • Consent from all legal guardians
  • Social insurance affiliation

Exclusion criteria

Exclusion Criteria:

  • Severe intellectual deficit (IQ\<30) or another uncontrolled comorbidity (e.g. epilepsy)
  • Recent change in ASD global care (cognitive behavioral therapy 6 weeks before inclusion)
  • Actual or past psychotropic medication
  • to colon preparation (Picoprep®) and/or to Meopa)
  • Severe or uncontrolled gastrointestinal symptoms (e.g. urgent treatment needed)
  • Undernutrition (age related \< 3rd percentile)
  • Inflammatory bowel disease
  • Exclusive diet (gluten- or sugar-free)
  • Rectal enema contraindication
  • Antibiotic or antifungal therapy 3 months before inclusion
  • Probiotics 2 months before inclusion or FMT 12 months before inclusion
  • Vancomycin or Picoprep® or Meopa (including ) known allergy or intolerance Experimental therapeutic trial participation 3 months before inclusion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Felictia Arm

    FMT

    Drug: FMT Protocol

Interventions

  • DrugFMT Protocol

    FMT protocol Samples (urine, blood, stool) collection Psychological examination Pediatric quality of life Scale Bristol Stool form Scale

06

What researchers measure

Primary outcomes

  1. Score of the Gastrointestinal Symptoms Rating Scale (GSRS)

    Assess initial efficacy on gastrointestinal (GI) symptoms of fecal microbiota transplantation (FMT) in children (36 to 72 months) with autism spectrum disorders (ASD (FMT) The Gastrointestinal Symptoms Rating Scale (GSRS) uses 15 items rated on a 7-point scale to assess gastrointestinal symptom severity, with total scores ranging from 15 (no symptoms) to 105 (very severe symptoms). Higher GSRS scores indicate more severe symptoms and a worse gastrointestinal outcome.

    Time frame: Week 18

Secondary outcomes

  1. Score of Vineland Adaptative Behavior Composite 3 scale

    Estimate the effect of FMT on autistic core symptoms and global functioning (socio adaptivecapacities, social cognition, repetitive and stereotyped behaviors) The Vineland Adaptive Behavior Scales (VABS) standard scores for each domain and the overall Adaptive Behavior Composite (ABC) range from 20 (minimum) to 160 (maximum), with a mean of 100 and a standard deviation of 15. Higher Vineland scores indicate better adaptive functioning and more positive outcomes, whereas lower scores reflect greater impairment in adaptive behavior

    Time frame: Day 0, Week 4, Week 18, Week 24, Month 12

  2. Score of Pediatric Adverse Event Rating Scale

    FMT side effects (antibiotic therapy, GM transplantation from a healthy donor): Pediatric Adverse Event Rating Scale \[evaluated by the investigator at day (D) 0, D5, W4, W18, W24, M12The Pediatric Adverse Event Rating Scale (PAERS) uses a combined score for each symptom that ranges from 0 (no symptom) to 5 (most severe/extreme symptom with impairment), based on symptom presence, functional impairment, and severity. Higher PAERS scores indicate more severe or impactful adverse events, representing a worse outcome\]

    Time frame: Day 0, Day 5, Week 4, Week 18, Week 24, Month 12

  3. Tolerability: Score of bristol Stool form

    Estimate FMT tolerability: completion of the FMT process and acceptability questionnaire (parents)

    Time frame: Day 0, Week 4, Week 18, Week 24, Month12

  4. Score of Pediatric Quality of Life Inventory

    Estimate FMT impact on children and parent's quality of life

    Time frame: Day 0, Week 18, Month 12

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Apr 2027, 19 months later.

Of 68 non-industry phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 63. This study's planned 19 months is below that.

Counting every sponsor, half of 83 studies reached it within 36 months; a quarter within 23 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Aug 5, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07105267
Collaborators
Fondation initiative autisme, Fondation Erie, Biocodex microbiota fondation
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Aug 5, 2025

Study contacts

Pierre ELLUL, MD
Contact
pierre.ellul@aphp.fr
0033140034635
Pierre ELLUL, MD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion